Posted by Michael Wonder on 05 Nov 2020
Forxiga approved in the EU for heart failure
5 November 2020 - Forxiga is the first SGLT2 inhibitor approved in the EU for heart failure with reduced ejection fraction in adult patients with and without type 2 diabetes mellitus.
AstraZeneca’s Forxiga (dapagliflozin) has been approved in the European Union for the treatment of symptomatic chronic heart failure with reduced ejection fraction in adults with and without type 2 diabetes mellitus.
